Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial design and controls.
Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for ...
Opinion
15dOpinion
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...
Zacks Investment Research on MSN
Replimune gets second FDA CRL for melanoma drug BLA, stock crashes
Replimune Group’s REPL share price is down 63% in the pre-market hours today after the company announced that the FDA has ...
As shares of Replimune Group (REPL) hit an all-time low on Monday of $1.50 following the US FDA's rejection of its lead ...
Feeling tired, bloated or sick? Nutritionists share fruits that may tackle common ailments and improve daily wellness.
Back in our day (I can already hear the groans of “oh no”, not a comparative dispatch from yesteryear, from the days of wine ...
In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results